Baseline characteristics of randomised population (ITT)
| Placebo(n = 318) | Salmeterol(n = 316) | |
|---|---|---|
| Figures are mean (SD) unless otherwise stated. | ||
| BDP, beclomethasone dipropionate; LABA, long acting β agonist; FEV1, forced expiratory volume in 1 second. | ||
| *Continued into the treatment period. | ||
| Age (years) | 62.3 (9.1) | 62.4 (9.2) |
| Men, n (%) | 242 (76%) | 242 (77%) |
| Weight (kg) | 74.8 (16.53) | 75.7 (16.58) |
| Duration of COPD (years) | 11.1 (8.1) | 11.2 (8.4) |
| Smoking status, n (%) | ||
| Current | 146 (46%) | 147 (47%) |
| Ex-smoker | 172 (54%) | 169 (53%) |
| Pack years | ||
| Current | 40.4 (18.2) | 40.7 (20.9) |
| Ex-smoker | 39.6 (25.9) | 38.1 (21.5) |
| Patients who continued any COPD medication,* n (%) | 282 (89%) | 271 (86%) |
| Patients taking inhaled corticosteroids,* n (%) | 191 (60%) | 172 (54%) |
| Daily dose BDP (μg) | 345 (235) | 319 (240) |
| Daily dose fluticasone (μg) | 273 (191) | 266 (182) |
| Daily dose budesonide (μg) | 345 (215) | 383 (297) |
| Daily dose flunisolide (μg) | 450 (71) | 375 (177) |
| Patients taking LABA, n (%) | 71 (22%) | 69 (22%) |
| Patients taking anticholinergics,* n (%) | 181 (57%) | 168 (53%) |
| Patients taking xanthines,* n (%) | 133 (42%) | 138 (44%) |
| Patients receiving non-COPD medication,* n (%) | 135 (42%) | 126 (40%) |
| Baseline FEV1 (l) | 1.3 (0.5) | 1.3 (0.5) |
| FEV1 (% predicted) | 45.8 (14.1) | 46.1 (14.5) |
| Reversibility (% predicted value) | 2.9 (3.6) | 3.3 (3.6) |